Incyte Reports Strong Q2 Earnings and Raises Full-Year Revenue Guidance
Incyte Corporation (NASDAQ:INCY) reported second-quarter net product sales of $1.49 billion in July 2026, a 40% increase year-over-year driven by strong demand across its portfolio and a one-time non-cash benefit from the resolution of a CMS matter involving OPZELURA. Excluding this $246 million benefit, net product sales still rose 17%, leading to an upward revision in full-year revenue guidance to between $5.13 billion and $5.26 billion. Jakafi remained a core growth driver with second-quarter sales of $817 million (up 7% year-over-year), while the business excluding Jakafi saw significant expansion, growing by 127% to $671 million. Products like OPZELURA and Niktimvo contributed strongly to this segment's performance. Incyte also raised its guidance for these products as well as for its hematology-oncology portfolio. The company expanded its pipeline through the acquisition of Vega Therapeutics, adding a phase III candidate latarcibart for von Willebrand disease. This and other development investments led to an increase in full-year operating expense guidance to $4.915 billion–$4.995 billion.
Tickers: $INCY
Topics: biotech financial performance guidance update pharmaceuticals